Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
129 hedge funds and large institutions have $343M invested in Synergy Pharmaceuticals, Inc Common Stock in 2015 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 51 increasing their positions, 36 reducing their positions, and 24 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 36
37% more call options, than puts
Call options by funds: $5.57M | Put options by funds: $4.08M
29% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 24
5% more funds holding
Funds holding: 123 → 129 (+6)
20% less capital invested
Capital invested by funds: $431M → $343M (-$88M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$25.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$25.8M |
| 3 |
PC
Paulson & Co
New York
|
+$24.9M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$12.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCMGA
York Capital Management Global Advisors
New York
|
-$15.4M |
| 2 |
BM
Bridger Management
New York
|
-$7.03M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$6.77M |
| 4 |
O
OrbiMed
New York
|
-$6.54M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$5.56M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FNYS
151
First New York Securities
New York
| – | -$8.3K | -1,000 | Closed |
|
|
GWM
152
Gupta Wealth Management
San Diego,
California
| – | -$2K | -270 | Closed |
|
153
Bank of Montreal
Toronto,
Ontario, Canada
| – | +$341 | +44 | New |
|
SGYP Hedge Fund Activity: Q3 2015 in Review
129 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q3 2015, worth a combined $343M — down 20% from $431M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new SGYP positions and 24 closed out — a net gain of 7 holders — while 51 added to existing stakes and 36 trimmed.
The largest buyer was State Street, adding an estimated $25.8M. The largest seller was York Capital Management Global Advisors, exiting entirely with an estimated $15.4M sold.
- 129 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q3 2015, up from 123 in Q2 2015.
- Funds reported $343M of Synergy Pharmaceuticals, Inc Common Stock stock for Q3 2015, down 20% quarter-over-quarter.
- 31 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q3 2015 and 24 closed out, a net change of +7 holders.
- The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q3 2015 was State Street, an estimated $25.8M added.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q3 2015 was York Capital Management Global Advisors, an estimated $15.4M sold.
Based on aggregated 13F filings for Q3 2015.